Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community …

A Torres, F Blasi, N Dartois, M Akova - Thorax, 2015 - thorax.bmj.com
Pneumococcal disease (including community-acquired pneumonia and invasive
pneumococcal disease) poses a burden to the community all year round, especially in those …

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease

D Mendes, A Averin, M Atwood, R Sato… - Expert Review of …, 2022 - Taylor & Francis
Objectives Despite the current pneumococcal vaccination program in England for older
adults and adults with underlying conditions, disease burden remains high. We evaluated …

[HTML][HTML] Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an …

PA Waight, NJ Andrews, SN Ladhani… - The Lancet infectious …, 2015 - thelancet.com
Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7) …

American association for the study of liver diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver …

OK Fix, EA Blumberg, KM Chang, J Chu… - …, 2021 - Wiley Online Library
The aim of this document is to provide a concise scientific review of the currently available
COVID‐19 vaccines and those in development, including mRNA, adenoviral vectors, and …

Rates of pneumococcal disease in adults with chronic medical conditions

KM Shea, J Edelsberg, D Weycker… - Open forum …, 2014 - academic.oup.com
Background. Although it is widely accepted that adults with immunocompromising conditions
are at greatly increased risk of pneumococcal infection, the extent of risk among …

[HTML][HTML] Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors

E Backhaus, S Berg, R Andersson, G Ockborn… - BMC infectious …, 2016 - Springer
Background Incidence, manifestations and case-fatality rate (CFR) of invasive
pneumococcal disease (IPD) vary with age and comorbidities. New vaccines, changing age …

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England

AJ Van Hoek, CL Sheppard, NJ Andrews, PA Waight… - Vaccine, 2014 - Elsevier
Abstract Background/Aims In April 2010 the 7-valent pneumococcal conjugate vaccine
(PCV7) was replaced by the 13-valent PCV. We investigated pneumococcal carriage in …

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

MJJ Mangen, MH Rozenbaum… - European …, 2015 - Eur Respiratory Soc
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated
the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine …

Vaccines for older adults

AL Cunningham, P McIntyre, K Subbarao, R Booy… - bmj, 2021 - bmj.com
The proportion of the global population aged 65 and older is rapidly increasing. Infections in
this age group, most recently with SARS-CoV-2, cause substantial morbidity and mortality …

[HTML][HTML] Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims …

MH Rozenbaum, MJJ Mangen, SM Huijts… - Vaccine, 2015 - Elsevier
Background Community-acquired pneumonia (CAP) is one of the most common acute
infections associated with a substantial clinical and economic burden. There have been few …